三阴性乳腺癌：神经激肽-1 受体拮抗剂如何用作新的治疗方法。

Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.

机构信息

Research Laboratory on Neuropeptides (IBIS), Virgen del Rocío University Hospital, Sevilla, Spain.

Institute of Neurosciences of Castilla y Leon (INCYL), Laboratory of Neuroanatomy of the Peptidergic Systems, University of Salamanca, Salamanca, Spain.

出版信息

Mini Rev Med Chem. 2020;20(5):408-417. doi: 10.2174/1389557519666191112152642.

DOI:10.2174/1389557519666191112152642

PMID:31721701

Abstract

Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death among females. BC cells not showing HER-2/Neu amplification and not expressing estrogen/ progesterone receptors are named triple-negative BC (TNBC) cells. TNBC represents 10-15% of all BC and is associated with an aggressive clinical course. TNBC patient prognosis, survival and response to current therapies are poor and for this reason, it is crucial to search for new therapeutic targets in TNBC to develop new therapeutic strategies. One of these targets is the neurokinin-1 receptor (NK-1R). It is well known that the substance P (SP)/NK-1R system is involved in cancer progression. TNBC cells overexpress the NK-1R and, after binding to this receptor, SP promotes the proliferation/ migration of TNBC cells. Non-peptide NK-1R antagonists (e.g., aprepitant) are known to exert, via the NK-1R, an antitumor action; TNBC cells die by apoptosis. In this review, we update the data on a promising therapeutic innovation: the use of NK-1R antagonists for the treatment of TNBC patients.

摘要

乳腺癌（BC）是最常见的癌症，也是女性癌症死亡的主要原因。不表现 HER-2/neu 扩增且不表达雌激素/孕激素受体的 BC 细胞被称为三阴性 BC（TNBC）细胞。TNBC 占所有 BC 的 10-15%，与侵袭性临床病程相关。TNBC 患者的预后、生存和对现有治疗的反应均较差，因此，寻找 TNBC 中的新治疗靶点以开发新的治疗策略至关重要。其中一个靶点是神经激肽-1 受体（NK-1R）。众所周知，P 物质（SP）/NK-1R 系统参与癌症进展。TNBC 细胞过度表达 NK-1R，SP 与该受体结合后促进 TNBC 细胞的增殖/迁移。已知非肽 NK-1R 拮抗剂（如阿瑞匹坦）通过 NK-1R 发挥抗肿瘤作用；TNBC 细胞通过细胞凋亡死亡。在这篇综述中，我们更新了关于一种有前途的治疗创新的资料：使用 NK-1R 拮抗剂治疗 TNBC 患者。